NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
8 trialsNCT02243358 2023-10-27
Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Henry Ford Health System
Phase 2 Completed
NCT01420874 2023-05-06
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT03666832 2022-06-15
MP-PDAC-01
Samsung Medical Center
Phase 1/2 Unknown
NCT03760614 2021-01-15
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Phase 1 Withdrawn
NCT02923921 2020-10-19
Sequoia
Eli Lilly and Company
Phase 3 Completed
NCT01632306 2019-01-15
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 1/2 Terminated
NCT01581307 2017-03-03
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed